Atypical protein kinase C phosphorylates par6 and facilitates transforming growth factor β-induced epithelial-to-mesenchymal transition

Molecular and Cellular Biology

Volumn 33, Issue 5, 2013, Pages 874-886

  Gunaratne, Adrian ^a   Thai, Boun L ^a   Di Guglielmo, Gianni M ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL PROTEIN KINASE C; PAR6 PROTEIN; PROTEIN; PROTEIN KINASE C; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SERINE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; STRESS FIBER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LUNG; LUNG NEOPLASMS; PHOSPHORYLATION; PROTEIN INTERACTION MAPPING; PROTEIN KINASE C; RATS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RHOA GTP-BINDING PROTEIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84874752022     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00837-12     Document Type: Article

References (56)

1. Guarino M, Rubino B, Ballabio G. 2007. The role of epithelialmesenchymal transition in cancer pathology. Pathology 39:305-318.
2. Thiery JP. 2002. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2:442-454.
3. Thiery JP, Sleeman JP. 2006. Complex networks orchestrate epithelialmesenchymal transitions. Nat. Rev. 7:131-142.
4. Huber MA, Kraut N, Beug H. 2005. Molecular requirements for epithelial- mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17:548-558.
5. Moreno-Bueno G, Portillo F, Cano A. 2008. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 27:6958-6969.
6. Thiery JP, Huang R. 2005. Linking epithelial-mesenchymal transition to the well-known polarity protein Par6. Dev. Cell 8:456-458.
7. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. 2005. TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir. Res. 6:56.
8. Levy L, Hill CS. 2006. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17:41-58.
9. Siegel PM, Massague J. 2003. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer 3:807-821.
10. Barrios-Rodiles M, Brown KR, Ozdamar B, Bose R, Liu Z, Donovan RS, Shinjo F, Liu Y, Dembowy J, Taylor IW, Luga V, Przulj N, Robinson M, Suzuki H, Hayashizaki Y, Jurisica I, Wrana JL. 2005. High-throughput.
11. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. 2005. Regulation of the polarity protein Par6 by TGF-β receptors controls epithelial cell plasticity. Science 307:1603-1609.
12. Viloria-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwage D, Roncari L, Narimatsu M, Bose R, Moffat J, Wong JW, Kerbel RS, O'Malley FP, Andrulis IL, Wrana JL. 2009. A role for the TGF-β-Par6 polarity pathway in breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 106:14028-14033.
13. Viloria-Petit AM, Wrana JL. 2010. The TGF-β-Par6 polarity pathway: linking the Par complex to EMT and breast cancer progression. Cell Cycle 9:623-624.
14. Bose R, Wrana JL. 2006. Regulation of Par6 by extracellular signals. Curr. Opin. Cell Biol. 18:206-212.
15. Etienne-Manneville S, Hall A. 2003. Cell polarity: Par6, aPKC, and cytoskeletal crosstalk. Curr. Opin. Cell Biol. 15:67-72.
16. Joberty G, Petersen C, Gao L, Macara IG. 2000. The cell-polarity protein Par6 links Par3 and atypical protein kinase C to Cdc42. Nat. Cell Biol. 2:531-539.
17. Lin D, Edwards AS, Fawcett JP, Mbamalu G, Scott JD, Pawson T. 2000. A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signaling and cell polarity. Nat. Cell Biol. 2:540-547.
18. Macara IG. 2004. Parsing the polarity code. Nat. Rev. 5:220-231. mapping of a dynamic signaling network in mammalian cells. Science 307:1621-1625.
19. Aranda V, Haire T, Nolan ME, Calarco JP, Rosenberg AZ, Fawcett JP, Pawson T, Muthuswamy SK. 2006. Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat. Cell Biol. 8:1235-1245.
20. Etienne-Manneville S, Hall A. 2001. Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCζ. Cell 106:489-498.
21. Etienne-Manneville S, Manneville JB, Nicholls S, Ferenczi MA, Hall A. 2005. Cdc42 and Par6-PKCζ regulate the spatially localized association of Dlg1 and APC to control cell polarization. J. Cell Biol. 170:895-901.
22. Gao L, Joberty G, Macara IG. 2002. Assembly of epithelial tight junctions is negatively regulated by Par6. Curr. Biol. 12:221-225.
23. Mu Y, Sundar R, Thakur N, Ekman M, Gudey SK, Yakymovych M, Hermansson A, Dimitriou H, Bengoechea-Alonso MT, Ericsson J, Heldin CH, Landstrom M. 2011. TRAF6 ubiquitinates TGF-β type I receptor to promote its cleavage and nuclear translocation in cancer. Nat. Commun. 2:330.
24. Nolan ME, Aranda V, Lee S, Lakshmi B, Basu S, Allred DC, Muthuswamy SK. 2008. The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. Cancer Res. 68:8201-8209.
25. Etienne-Manneville S. 2008. Polarity proteins in migration and invasion. Oncogene 27:6970-6980.
26. Wang HR, Zhang Y, Ozdamar B, Ogunjimi AA, Alexandrova E, Thomsen GH, Wrana JL. 2003. Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. Science 302:1775-1779.
27. Ono Y, Fujii T, Ogita K, Kikkawa U, Igarashi K, Nishizuka Y. 1989. Protein kinase C zeta subspecies from rat brain: its structure, expression, and properties. Proc. Natl. Acad. Sci. U. S. A. 86:3099-3103.
28. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango- Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. 2005. Atypical PKCι contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 102:12519-12524.
29. Fields AP, Frederick LA, Regala RP. 2007. Targeting the oncogenic protein kinase Cι signaling pathway for the treatment of cancer. Biochem. Soc. Trans. 35:996-1000.
30. Fields AP, Regala RP. 2007. Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol. Res. 55:487-497.
31. Frederick LA, Matthews JA, Jamieson L, Justilien V, Thompson EA, Radisky DC, Fields AP. 2008. Matrix metalloproteinase-10 is a critical effector of protein kinase Cι-Par6α-mediated lung cancer. Oncogene 27: 4841-4853.
32. Patel R, Win H, Desai S, Patel K, Matthews JA, Acevedo-Duncan M. 2008. Involvement of PKC-ι in glioma proliferation. Cell Prolif. 41:122-135.
33. Regala RP, Thompson EA, Fields AP. 2008. Atypical protein kinase Cι expression and aurothiomalate sensitivity in human lung cancer cells. Cancer Res 68:5888-5895.
34. Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, Fields AP. 2005. Atypical protein kinase Cι plays a critical role in human lung cancer cell growth and tumorigenicity. J. Biol. Chem. 280:31109-31115.
35. Gunaratne A, Benchabane H, Di Guglielmo GM. 2012. Regulation of TGF-β receptor trafficking and signaling by atypical protein kinase C. Cell Signal. 24:119-130.
36. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. 2000. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-β receptor for degradation. Mol. Cell 6:1365-1375.
37. Babwah AV, Dale LB, Ferguson SS. 2003. Protein kinase C isoformspecific differences in the spatial-temporal regulation and decoding of metabotropic glutamate receptor 1a-stimulated second messenger responses. J. Biol. Chem. 278:5419-5426.
38. Rozen S, Skaletsky H. 2000. Primer3 on theWWWfor general users and for biologist programmers. Methods Mol. Biol. 132:365-386.
39. Spandidos A, Wang X, Wang H, Dragnev S, Thurber T, Seed B. 2008. A comprehensive collection of experimentally validated primers for polymerase chain reaction quantitation of murine transcript abundance. BMC Genomics 9:633. doi:10.1186/1471-2164-9-633.
40. Spandidos A, Wang X, Wang H, Seed B. PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res. 38:D792-D799.
41. Wang X, Seed B. 2003. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 31:e154.
42. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
43. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3:RESEARCH0034.
44. Saviozzi S, Cordero F, Lo Iacono M, Novello S, Scagliotti GV, Calogero RA. 2006. Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer. BMC Cancer 6:200. doi:10.1186/1471-2407-6-200.
45. To C, Kulkarni S, Pawson T, Honda T, Gribble GW, Sporn MB, Wrana JL, Di Guglielmo GM. 2008. The synthetic triterpenoid 2-cyano-3,12- dioxooleana-1,9-dien-28-oic acid-imidazolide alters transforming growth factor beta-dependent signaling and cell migration by affecting the cytoskeleton and the polarity complex. J. Biol. Chem. 283:11700-11713.
46. Sumimoto H, Kamakura S, Ito T. 2007. Structure and function of the PB1 domain, a protein interaction module conserved in animals, fungi, amoebas, and plants. Sci. STKE 2007:re6.
47. Henrique D, Schweisguth F. 2003. Cell polarity: the ups and downs of the Par6/aPKC complex. Curr. Opin. Genet. Dev. 13:341-350.
48. Noda Y, Kohjima M, Izaki T, Ota K, Yoshinaga S, Inagaki F, Ito T, Sumimoto H. 2003. Molecular recognition in dimerization between PB1 domains. J. Biol. Chem. 278:43516-43524.
49. Wilson MI, Gill DJ, Perisic O, Quinn MT, Williams RL. 2003. PB1domain-mediated heterodimerization in NADPH oxidase and signaling complexes of atypical protein kinase C with Par6 and p62. Mol. Cell 12: 39-50.
50. Cheng PL, Lu H, Shelly M, Gao H, Poo MM. 2011. Phosphorylation of E3 ligase Smurf1 switches its substrate preference in support of axon development. Neuron 69:231-243.
51. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K. 2001. Smurf1 interacts with transforming growth factorbeta type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276:12477-12480.
52. Stiess M, Bradke F. 2011. Controlled demolition: Smurf1 regulates neuronal polarity by substrate switching. Neuron 69:183-185.
53. Hirai T, Chida K. 2003. Protein kinase Cζ (PKCζ): activation mechanisms and cellular functions. J. Biochem. 133:1-7.
54. Li Q, Wang JM, Liu C, Xiao BL, Lu JX, Zou SQ. 2008. Correlation of aPKC-ι and E-cadherin expression with invasion and prognosis of cholangiocarcinoma. Hepatobiliary Pancreat. Dis. Int. 7:70-75.
55. Erdogan E, Lamark T, Stallings-Mann M, Lee J, Pellecchia M, Thompson EA, Johansen T, Fields AP. 2006. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Cι. J. Biol. Chem. 281:28450-28459.
56. Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, Lohse CM, Fields AP. 2005. Atypical protein kinase Cι is an oncogene in human non-small cell lung cancer. Cancer Res. 65:8905-8911.